Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,109 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug testing Clear all
Suspended Phase 2 Interventional

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

NCT06050252
View directory record Official record
Conditions
Resectable Intrahepatic Cholangiocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Resection
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
57
States / cities
Irvine, California • Los Angeles, California • Orange, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions
IPN01194
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors

NCT05582551
View directory record Official record
Conditions
Childhood Cancer
Interventions
Highlighting Patients at Risk for Sensory Screening (HPARSS)
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial and Aging Effects of Acute Antioxidant Supplementation

NCT02157207
View directory record Official record
Conditions
Healthy
Interventions
Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 18, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Drug · Other
Lead sponsor
Razor Genomics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

BD MiniDraw™ Capillary System Clinical Equivalence Study

NCT05186311
View directory record Official record
Conditions
Healthy, Disease, Chronic, Acute Disease, Sample Collection
Interventions
Capillary Blood Collection System
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 18, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers

NCT05279053
View directory record Official record
Conditions
Sex, Cigarette Smoking
Interventions
Abstinence and Smoking
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

NCT05877300
View directory record Official record
Conditions
Esophageal Diseases
Interventions
CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
Combination Product
Lead sponsor
Harvard Apparatus Regenerative Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Results available

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia, B-Non Hodgkin Lymphoma, B-NHL, B-All, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide, Apheresis, Anti-emetic, Diphenhydramine, Acetaminophen, ECG, ECHO, MRI Brain, Bone marrow biopsy, Cardiac MRI
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

NCT07261371
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Withdrawn Not applicable Interventional

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

NCT04205786
View directory record Official record
Conditions
HR-positive Breast Cancer
Interventions
Vitamin B12, Blood collection, Brief Pain Inventory - Short Form survey, FACT-ES Trial Outcome Index (Version 4), Questionnaire to Assess Adherence to Aromatase Inhibitors, Demographics Questionnaire
Dietary Supplement · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

New MRI Biomarkers in Head and Neck Cancers

NCT03483337
View directory record Official record
Conditions
Head and Neck Cancer, Thyroid Cancer
Interventions
MRI examinations
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Juntos/Together Program to Build Confidence for Complex Care Tasks Among Latino Family Caregivers

NCT05582473
View directory record Official record
Conditions
Dementia Caregivers
Interventions
LST-LC Education
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gathering Online for Dialogue and Discussion to Enhance Social Support

NCT05753683
View directory record Official record
Conditions
Alcohol Misuse, HIV, Sexually Transmitted Infections, Pre-exposure Prophylaxis
Interventions
mHealth-Women's CoOp, Virtual Group
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years to 30 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18348-Human Phototoxicity Test

NCT02823483
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Lotion (BAY987521), Untreated Skin
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ibuprofen 5% Topical Gel CIPT

NCT01771822
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional

WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers

NCT04587583
View directory record Official record
Conditions
Dementia, Caregiver, Memory Disorders, Alzheimer Disease, Behavioral Symptoms
Interventions
WeCareAdvisor
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Not applicable Interventional

Discharge Educational Strategies for Reduction of Vascular Events

NCT01836354
View directory record Official record
Conditions
Intracerebral Infarcts, Ischemic Stroke, Hemorrhagic Strokes, TIA's
Interventions
DESERVE education
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

NCT03775954
View directory record Official record
Conditions
High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions
Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
Diagnostic Test · Genetic
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 18, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Results available

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

NCT03523572
View directory record Official record
Conditions
Breast Cancer, Urothelial Carcinoma
Interventions
Trastuzumab deruxtecan, Nivolumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 18, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 18, 2026, 1:09 AM EDT